Mesoblast operational and financial highlights for quarter ended december 31, 2020

New york, jan. 28, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the second quarter ended december 31, 2020.
MESO Ratings Summary
MESO Quant Ranking